Protokoly_diagnostiki_i_lechenia_zabolevany

( %

: 06-077

"$ &: ": 6!

& !: , & " , , "

$ : " " $ $ "$ ( # % 2 )

* : L , " % " , %# & # .

: & &1-2 , % & G# "- $# ;; & ; " . > #, & & (1,4).

" & :

1.# ( , , ! 7)

2.? 'BL

3.B $ &

6.; " 3

7.@ "

8.% " $

9.B

" & & :

+ :

, & " , ," " .

& # % & & $# :+ & # & ;

! ;

H % ;

+ & # & .

$" , , & $, % & . ; " " " ( , ,, " , , .

' – .– .

" & :

1. < ?- $ V 500 >@,

2. B 5 , 10 , 20 , 40 , 60 ; V 0,1% 10 ; 3 &

" & & :,- !:

G " " , # # %$#$, %$% , %$#$ % .

/ , & :

1." + " " / . B.+. @ , M.J. K " . – 6.: 7 ;?-6>@, 2004. (! «@ & »);

2.@ & . >% " . L & 1. 6 , 6 ! , 2003;

3.Prodigy Guidance – Anal Fissure, 2005;

4.EBM Guidelines. Anal fissure, 2005.

* – , # (% % ) .

7 8

: 02-026

"$ &: "

: 6!

& !: c & .

(: H35.3 @ $

H36.8 @ & ,

) : 7 8 - 3 " "# % <3 .

$ : "$ 3 : $, 3$ $. * : " . B$# " '@D % . ? & . .

:

? " , V ( & " :, #&$ # , & ). , $ . % , , & , & " : , & " % %-, , & 3 , , ".

" & :

1.& &

3.<

5.&

6.&

7.;

" & & :

2.;

3.H)B

4._ $

5.&

6.&$ ( " )

+ :

7 & " [1]. # : J [2]

7 & : J " ( " &$)," " # ,

( ). 3 % 0,5 – .

+ "$ , "$#& # " : , "% .

? : 3 0,5 & - 10 ; 0,5& - 10 ; 1 3 &, 10 ;

& - 0,5 - 10 , 1 3 & 30 1,0 / - 10 . @ "& . '" .

" - " $ $" % .

" & :

1.7 ,

2.*; 4% ( ) 1

3. *; 1 5%, 10%, 30%50%

4.6 V 500 ,

5.*@ "& V 40 /

10%, 20%

" & & :,- ! (! ): ".

/ , & :

1.American Academy of Ophthalmology. Guideline. Age-Related Macular Degeneration. 2003.

2.EBM Guidelines. Age-related macular degeneration (ARMD). 2004.

3.International Council of Ophthalmology. ICO Clinical Guidelines: Age-related macular degeneration (Initial and follow-up evaluation).

4.Olk RJ, Friberg TR, Stickney KL et al. Therapeutic benefits of infrared (810 nm) diode laser macular grid photocoagulation in prophilactic treatment of non-exudative age-related macular degeneration: two-year results of a randomised pilot study.

Ophthalmology 1999; 106: 1367-1373.

5.@ & . >% " . 2003 - L & 7. - !. 2322-2339.

* – , # (% % ) .

1.H" # " , " %% % .

6., 3 , 3 .

7.! % , " " 3 & & " .

8.J # " .

9.< & & % .

10. ' % & " & & % & .

11.< & " , " .

12.H)B: " .

" & :

1.# (6 )

2.# "

3.H)B & %

4.& &

5.! & %

6. B " % & %

7.2- : "

8.< " " %

9.!?

10./

11.B_?

" & & :

1.; & H)B

2./

3.&$

4.< & %

5.B $

6.; %%

7.? " &

8.H)B "

+ :

1.J 3 " ( " &

+ , ( , , , ), .

2.@ " && 400 \ " 7 .

3.- ( , 1-2 2,5 1 & 2,5

1-2 ) " & ).

4..

5.6 % & % , " , "( ).

3.*B & 150 – 10 \

4.+ 200

5." &

6.*6 , 250

7.*? 250 ; 250 , 500 ; V 500 , 1000 ; 125/5

" & & :

1. *? 200 ; 205

2.7 % 3 1

3.*J 250 , 500

,- ! : 3 &

/ , & :

1.Chronic prostatitis. Thomas Jang and Anthony Schaeffer. Search date July 2004. BMJ;

2.Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998; 159: 883-887;

3.Prodigy Guidance - Prostatitis

4.Hanus PM, Danzinger LH. Treatment of chronic bacterial prostatitis. Clin Pharm 1984; 3: 4955;

5.McNaughton, C.M. and Wilt, T. (2001) Allopurinol for chronic prostatitis (Cochrane Review). The Cochrane Library (Issue 1). Oxford: Update Software;

6.Collins M, MacDonald R, Wilt T. Diagnosis and treatment of chronic abacterial prostatitis: a

systematic review. Ann Intern Med 2000; 133: 367-368;

7. McNaughton Collinns M, MacDonald R, Wilt T. Interventions for chronic abacterial prostatitis. In: The Cochrane Library, Issue 3, 2001.

* – , # (% % ) .

7 & 8 8

: 08-098

"$ &: "

: 6!

& ! : " % . " , % , , .

(:

L02 ? % ,

L03 _

L04

L72 _ % % "

L88

N64 @ " %

T00 , $# &

S01.0 "

T01 , $# &

T06 @ , $# & ,

T07 6 % "

T11 @ " "

T13 @ % " "

L02.2 ? % , #

L03.0 _ &

L08.0

L08.9 6 % % " "

) : # - " , $# " " # " .

* - -" %$# . ' & &$ % %$#$ &$ &.

- -" & "

& $ .

" – $# , " , " % & , % . ' , ,, " " , $ - " , %$ " .

$ & : -? " - -"

- "$: , " 3 " : V , " . .

* : $ " . " % &, % .

: " &, , % , &.

" & :

2.6

" & :

+ : 7 & . 7 & : $ / ,,$ & ,$# 3 & "$# , " " ,% $# . 7 & "$# , % % , 3 "" % $# .

1.7

2.? " " & .

3. ; " % .

4.J " ( ) " .

5.B " " , % % , " .

" & :

1.*? V 5%, 10% 2 , 5

2._ 500

3.*? + 625 ; V 600

4. */ 250 , 500 , ; 125 , 250 /5

5.*/ 250 , 500 ; V750

9.*B & 150 – 10 \

10.2% &

11.2% &

12.*+ & V 30% 5 , 10

13.*+ 50 ; 1% 1

14.*? & 250

15.+ 30 , 50

16.*6 10% &

17.*6 250 ; 0,5 100

18.500

19., % 4 500 >@

20.*@ 200 , 400

21.7 &

22.*6 1% 10

23.* 1:10 000

24.* & 3% 25 , 40

25.5% @

" & & :,- !: ,

/ , & :

1.Colour atlas and synopsis of clinical dermatology.User’s Manual. CD-ROM. The VcGraw-Hill Company, Inc. 1997.

2.Jorup-Ronstrom C, Britton A, Gavlevik K, Gunnarsson K, Redman AC. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12: 390-394

3.Vinen J, Hudson B, Chan B, Fernandes C. A randomized comparative study of once-daily ceftriaxone and 6-hourly flucloxacillin in the treatment of moderate to severe cellulitis. Clinical efficacy, safety and pharmacoeconomic implications. Clin Drug Invest 1996; 12: 221-225.

* – , # (% % ) .

7

: 17-171

"$ &: "

: 6!

& ! : , . ' "$, & % % & & % %

$ : , % , % % ,, % ( " , " ). '% "$: , % , . >

1. H # & & .

2. " " & & , .

3.+ % & %

4.% &

5.+ " " .

" %

+ % , #$ & &

$ " &. 3 & & % " .